Comprehensive Cancer Center - Innate Immunity

Research output

Research output per year 1972 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

• 488752 Citations
• 287 h-index
• 5593 Article
• 590 Review article
• 236 Letter
• 184 Comment/debate
• 440 More
  • 111 Conference contribution
  • 108 Chapter
  • 89 Paper
  • 59 Editorial
  • 40 Conference article
  • 31 Short survey
  • 1 Book
  • 1 Foreword/postscript

Research output per year

Research output per year

Search results

• 2025

  Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial

  Pemmaraju, N., Konopleva, M., Sweet, K. L., Stein, A. S., Rizzieri, D. A., Wang, E. S., Vasu, S., Rosenblat, T. L., Tosolini, A., Gupta, I. & Lane, A. A., 2025, (Accepted/In press) In: Leukemia and Lymphoma.

  Research output: Contribution to journal › Letter › peer-review

• Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma

  Chowdhury, S. M., Bhatta, S., Voorhees, T. J., Annunzio, K., Bond, D. A., Sawalha, Y., Sigmund, A., Hanel, W., Sehgal, L., Alinari, L., Baiocchi, R., Maddocks, K., Christian, B., Jones, D. & Epperla, N., Dec 2025, In: Journal of Hematology and Oncology. 18, 1, 4.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Newly Diagnosed 100%
  • Diffuse Large B-cell Lymphoma (DLBCL) 100%
  • Lymphoma Cells 100%
  • Working Diagnosis 100%
  • De Novo Diffuse Large B-cell Lymphoma 100%
• 2024

  BRAF V600E gene mutation is present in primary intraosseous Rosai-Dorfman disease

  Cevik, L., Satturwar, S., Jones, D., Mayerson, J., Oghumu, S. & Iwenofu, O. H., Dec 2024, In: Human Pathology. 154, 105702.

  Research output: Contribution to journal › Letter › peer-review

• CD56 expression predicts response to Daratumumab-based regimens

  Robinette, A. J., Huric, L., Dona, K., Benson, D. & Cottini, F., Dec 2024, In: Blood Cancer Journal. 14, 1, 62.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations

• Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia

  Avenarius, M. R., Huang, Y., Kittai, A. S., Bhat, S. A., Rogers, K. A., Grever, M. R., Woyach, J. A. & Miller, C. R., Mar 2024, In: Leukemia. 38, 3, p. 676-678 3 p.

  Research output: Contribution to journal › Letter › peer-review

• DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

  Su, P. L., Chakravarthy, K., Furuya, N., Brownstein, J., Yu, J., Long, M., Carbone, D., Li, Z. & He, K., Dec 2024, In: Molecular cancer. 23, 1, 97.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • DLL3 100%
  • Small Cell Lung Cancer 100%
  • Antibody-drug Conjugate 100%
  • Radioimmunotherapy 100%
  • Guided Therapy 100%
  14 Scopus citations

• Hairy cell leukemia variant and WHO classification correspondence Re: 5^th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

  Grever, M., Andritsos, L., Anghelina, M., Arons, E., Banerji, V., Barrientos, J., Bhat, S. A., Blachly, J., Broccoli, A., Call, T., Dearden, C., Dietrich, S., Else, M., Epperla, N., Fagarasanu, A., Falini, B., Forconi, F., Gozzetti, A., Hampel, P. & Hermel, D. J. & 25 others, Iyengar, S., Johnston, J. B., Juliusson, G., Kreitman, R. J., Lauria, F., Lozanski, G., Oakes, C. C., Parikh, S. A., Park, J., Quest, G., Rai, K., Ravandi, F., Robak, T., Rogers, K. A., Saven, A., Seymour, J. F., Tadmor, T., Tallman, M. S., Tam, C. S., Tiacci, E., Troussard, X., Wörmann, B., Zent, C. S., Zenz, T. & Zinzani, P. L., Jul 2024, In: Leukemia. 38, 7, p. 1642-1644 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  7 Scopus citations

• Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model

  Archer, K. J., Fu, H., Mrózek, K., Nicolet, D., Mims, A. S., Uy, G. L., Stock, W., Byrd, J. C., Hiddemann, W., Braess, J., Spiekermann, K., Metzeler, K. H., Herold, T. & Eisfeld, A. K., Dec 2024, In: Journal of Hematology and Oncology. 17, 1, 28.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • High Risk 100%
  • Low Risk 100%
  • Relapse Risk 100%
  • Long-term Survivors 100%
  • Mixture Cure Model 100%

• Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study

  Badar, T., Narra, R., Mims, A. S., Heckman, M. G., Shallis, R. M., Fahad, S., Hunter, C., Kota, V., Othman, T. A., Jonas, B., Desai, S., de Camargo Correia, G. S., Patel, A., DuVall, A. S., Palmisiano, N., Curran, E., Omer, Z., Advani, A., Atallah, E. & Litzow, M., Dec 2024, In: American Journal of Hematology. 99, 12, p. 2388-2391 4 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• NTRK-rearranged mesenchymal tumour in oesophagus with DOG1 immunohistochemical expression: is it a gastrointestinal stromal tumour?

  Challa, B., Jones, D., Kim, A. C., D'Souza, D. M. & Esnakula, A. K., Jun 2024, In: Pathology. 56, 4, p. 602-604 3 p.

  Research output: Contribution to journal › Letter › peer-review

• Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis

  Epperla, N., Zhao, Q., Moyo, T., Watkins, M. P., Tavakkoli, M., Bello, C., Torka, P., Reddy, N., Thomas, C., Annunzio, K., Christian, B., Barta, S. K., Shouse, G., Olszewski, A. J. & Bartlett, N. L., Feb 13 2024, In: Blood Advances. 8, 3, p. 549-552 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis

  Kittai, A. S., Hang, Y., Bhat, S. A., Clark, A., Grever, M., Rhodes, J. M., Roberts, M., Rogers, K. A., Teschemaker, A., Munoz-Sagastibelza, M., Woyach, J. A. & Barrientos, J. C., Apr 2024, In: American Journal of Hematology. 99, 4, p. 780-784 5 p.

  Research output: Contribution to journal › Letter › peer-review

• Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials

  Carr, L., Norris, K., Parker, H., Nilsson-Takeuchi, A., Bryant, D., Amarasinghe, H., Kadalayil, L., Else, M., Pettitt, A., Hillmen, P., Schuh, A., Walewska, R., Baird, D. M., Oscier, D. G., Oakes, C. C., Gibson, J., Pepper, C. & Strefford, J. C., Nov 2024, In: British Journal of Haematology. 205, 5, p. 2072-2076 5 p.

  Research output: Contribution to journal › Letter › peer-review

• White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years

  Ozga, M., Nicolet, D., Mrózek, K., Walker, C. J., Blachly, J. S., Kohlschmidt, J., Orwick, S., Carroll, A. J., Larson, R. A., Kolitz, J. E., Powell, B. L., Stone, R. M., Byrd, J. C., Eisfeld, A. K. & Mims, A. S., Nov 2024, In: American Journal of Hematology. 99, 11, p. 2236-2240 5 p.

  Research output: Contribution to journal › Letter › peer-review
• 2023

  A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

  Kittai, A. S., Skarbnik, A., Miranda, M., Yong, A. S. M., Roos, J., Hettle, R., Palazuelos-Munoz, S., Shetty, V. & Ghia, P., Dec 2023, In: American Journal of Hematology. 98, 12, p. E387-E390

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  8 Scopus citations

• Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

  Meyers, G., Hamadani, M., Martens, M., Ali, H., Chevallier, P., Choe, H., Harris, A. C., Holler, E., van Hooren, E., Klaassen, W., Leifer, E., van Oosterhout, Y., Perez, L., Pusic, I., Stelljes, M., van der Velden, W., Ammatuna, E., Beauvais, D., Cornillon, J. & Maziarz, R. T. & 5 others, Schetelig, J., Romeril, J., MacMillan, M. L., Levine, J. E. & Socié, G., Dec 2023, In: Bone Marrow Transplantation. 58, 12, p. 1416-1418 3 p.

  Research output: Contribution to journal › Letter › peer-review
  2 Scopus citations

• Association of social deprivation with survival in younger adult patients with AML: an Alliance study

  Rebechi, M., Kohlschmidt, J., Mrózek, K., Nicolet, D., Mims, A. S., Blachly, J. S., Orwick, S., Larkin, K. T., Oakes, C. C., Hantel, A., Carroll, A. J., Blum, W. G., Powell, B. L., Uy, G. L., Stone, R. M., Larson, R. A., Byrd, J. C., Paskett, E. D., Plascak, J. J. & Eisfeld, A. K., Aug 8 2023, In: Blood Advances. 7, 15, p. 4019-4023 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  6 Scopus citations

• Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma

  Ozga, M., Zhao, Q., Huric, L., Miller, C., Rosko, A., Khan, A., Umyarova, E., Benson, D. & Cottini, F., Dec 2023, In: Blood Cancer Journal. 13, 1, 167.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  5 Scopus citations

• Correspondence comprehensive characterization of a brainstem aggregoma (light and heavy chain deposition disease)

  Becker, A. P., Osorio, D. S., Bell, E. H., Giglio, P., Fleming, J. L., Cottrell, C. E., Mardis, E. R., Miller, K. E., Schieffer, K. M., Kelly, B. J., Makary, M. S., Slone, W., Benson, D., Leonard, J., Kahwash, S. B., Boué, D. R. & Chakravarti, A., Sep 2023, In: Brain Pathology. 33, 5, e13154.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations

• Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine

  Himed, S., Chung, C., Dulmage, B., Jaglowski, S., Bond, D., Maddocks, K. & Kaffenberger, B. H., Jul 2023, In: Journal of the European Academy of Dermatology and Venereology. 37, 7, p. e890-e893

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• Dupilumab for refractory sclerotic-type cutaneous graft-versus-host disease

  Mital, R., Penza, S. L., Choe, H. K., Chung, C. G. & Kaffenberger, B. H., Nov 2023, In: Journal of the European Academy of Dermatology and Venereology. 37, 11, p. e1323-e1324

  Research output: Contribution to journal › Letter › peer-review
  3 Scopus citations

• Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

  Bhatnagar, B., Kohlschmidt, J., Orwick, S. J., Buelow, D. R., Fobare, S., Oakes, C. C., Kolitz, J. E., Uy, G., Stock, W., Powell, B. L., Nicolet, D., Hertlein, E. K., Mrózek, K., Blachly, J. S., Eisfeld, A. K., Baker, S. D. & Byrd, J. C., Aug 16 2023, In: Blood Advances. 7, 16, p. 4671-4675 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  4 Scopus citations

• IDH2 R140Q mutation associated with palisaded neutrophilic and granulomatous dermatitis with subsequent development of IDH2-mutated acute myeloid leukemia

  Himed, S., Chung, C., Jones, D., Wall, S. & Kaffenberger, B. H., Apr 2023, In: International Journal of Dermatology. 62, 4, p. e217-e219

  Research output: Contribution to journal › Letter › peer-review

• Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

  Espinoza-Gutarra, M., Saad, A. & Jamy, O., Apr 10 2023, In: Stem Cell Investigation. 10, 8

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations

• Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study

  Annunzio, K., Grover, N. S., Welkie, R. L., Torka, P., Watkins, M. P., Anampa-Guzmán, A., Tavakkoli, M., Oh, T. S., Reves, H., Jones, D., Hanel, W., Christian, B., Geethakumari, P. R., Karmali, R., Barta, S. K., Bartlett, N. L., Olszewski, A. J. & Epperla, N., 2023, In: Blood Advances. 7, 22, p. 6839-6843 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  2 Scopus citations

• Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

  Epperla, N., Welkie, R. L., Torka, P., Shouse, G., Karmali, R., Shea, L., Anampa-Guzmán, A., Oh, T. S., Reaves, H., Tavakkoli, M., Lindsey, K., Greenwell, I. B., Hansinger, E., Thomas, C., Chowdhury, S. M., Annunzio, K., Christian, B., Barta, S. K., Geethakumari, P. R. & Bartlett, N. L. & 3 others, Herrera, A. F., Grover, N. S. & Olszewski, A. J., Dec 2023, In: Journal of Hematology and Oncology. 16, 1, 49.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Disease Progression 100%
  • Marginal Zone Lymphoma 100%
  • Early Relapse 100%
  • First-line Systemic Therapy 100%
  • Systemic Therapy 100%
  9 Scopus citations

• Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis

  Epperla, N., Zhao, Q., Anghelina, M., Neal, J., Blachly, J. S., Rogers, K. A., Lozanski, G., Oakes, C. C., Bhat, S. A., Zent, C. S., Banerji, V., Grever, M. & Andritsos, L. A., May 2023, In: American Journal of Hematology. 98, 5, p. E116-E118

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  4 Scopus citations

• Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma

  Khan, A. M., Dvorak, K., Zhao, Q., Bumma, N., Cottini, F., Devarakonda, S., Umyarova, E., Sharma, N., Benson, D. & Rosko, A., Dec 2023, In: Haematologica. 108, 12, p. 3477-3479 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations

• Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

  Epperla, N., Feng, L., Shah, N. N., Fitzgerald, L., Shah, H., Stephens, D. M., Lee, C. J., Ollila, T., Shouse, G., Danilov, A. V., David, K. A., Torka, P., Hashmi, H., Hess, B., Barta, S. K., Romancik, J. T., Cohen, J. B., Annunzio, K., Kittai, A. S. & Reneau, J. & 9 others, Zurko, J., Nizamuddin, I. A., Winter, J. N., Gordon, L. I., Ma, S., Patel, R., Nastoupil, L., Ahmed, S. & Karmali, R., Dec 2023, In: Journal of Hematology and Oncology. 16, 1, 111.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Multicenter Cohort Study 100%
  • Secondary Central Nervous System Lymphoma 100%
  • Cytokine Release Syndrome 100%
  • CAR T-cell Therapy 100%
  • Central Nervous System 100%
  19 Scopus citations

• Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

  Saliba, A. N., Kaufmann, S. H., Stein, E. M., Patel, P. A., Baer, M. R., Stock, W., Deininger, M., Blum, W., Schiller, G. J., Olin, R. L., Litzow, M. R., Lin, T. L., Ball, B. J., Boyiadzis, M. M., Traer, E., Odenike, O., Arellano, M. L., Walker, A., Duong, V. H. & Kovacsovics, T. & 20 others, Collins, R. H., Shoben, A. B., Heerema, N. A., Foster, M. C., Peterson, K. L., Schneider, P. A., Martycz, M., Gana, T. J., Rosenberg, L., Marcus, S., Yocum, A. O., Chen, T., Stefanos, M., Mims, A. S., Borate, U., Burd, A., Druker, B. J., Levine, R. L., Byrd, J. C. & Foran, J. M., Jun 13 2023, In: Blood Advances. 7, 11, p. 2360-2363 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  10 Scopus citations

• Postibrutinib relapse outcomes for patients with marginal zone lymphoma

  Epperla, N., Zhao, Q., Chowdhury, S. M., Shea, L., Moyo, T. K., Reddy, N., Sheets, J., Weiner, D. M., Geethakumari, P. R., Kandarpa, M., Bruno, X. J., Thomas, C., Churnetski, M. C., Hsu, A., Zurbriggen, L., Tan, X. W. C., Lindsey, K., Maakaron, J., Caimi, P. F. & Torka, P. & 26 others, Bello, C., Ayyappan, S., Oh, T. S., Karmali, R., Kim, S. H., Kress, A., Kothari, S., Sawalha, Y., Christian, B., David, K. A., Greenwell, I. B., Janakiram, M., Kenkre, V. P., Olszewski, A. J., Cohen, J. B., Palmisiano, N., Umyarova, E., Wilcox, R. A., Awan, F. T., Alderuccio, J. P., Barta, S. K., Grover, N. S., Ghosh, N., Bartlett, N. L., Herrera, A. F. & Shouse, G., Jan 10 2023, In: Blood Advances. 7, 1, p. 88-91 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations

• Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results

  Avenarius, M. R., Huang, Y., Hyak, J., Byrd, J. C., Bhat, S. A., Grever, M., Kittai, A. S., Rogers, K. A., Jones, D., Zhao, W., Heerema, N. A., Abruzzo, L. V., Woyach, J. & Miller, C. R., Oct 2023, In: Hematological Oncology. 41, 4, p. 771-775 5 p.

  Research output: Contribution to journal › Letter › peer-review

  • Confidence Interval 100%
  • Chronic Lymphocytic Leukemia 100%
  • Hazard Ratio 100%
  • Fluorescence in Situ Hybridization 100%
  • B-Cell Chronic Lymphocytic Leukemia 100%

• Relationship between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

  Gopalakrishnan, S., Menon, R., Suleiman, A. A., Kater, A. P., Stilgenbauer, S., Seymour, J. F., Chyla, B., Lu, T., Young Kim, S., Roberts, A. W., Woyach, J. A., Mensing, S. & Salem, A. H., Dec 17 2023, In: HemaSphere. 7, 12, p. E983

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Response to Letter to the Editor: A Comparison of Risk Factors for Septic Arthritis in Immunocompromised Patients: A Single Institution Study

  Brown, C. R., Samade, R., Larkin, K. T. M. & Speeckaert, A. L., Jun 1 2023, In: Journal of the American Academy of Orthopaedic Surgeons. 31, 11, p. E523-E524

  Research output: Contribution to journal › Letter › peer-review

• Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy

  Annunzio, K., Cackovic, M., Bond, D., Sawalha, Y., Voorhees, T. J., Hanel, W., Alinari, L., Baiocchi, R., Reneau, J., Brammer, J., Maddocks, K., Christian, B. & Epperla, N., May 23 2023, In: Blood Advances. 7, 10, p. 2241-2244 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations

• TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma

  Gordon, M. J., Bond, D. A., Kittai, A. S., Amirmokhtari, N., Steinbrunner, A., Huffman, A., Orellana-Noia, V., Shouse, G., Cohen, J. B., Phillips, T. & Danilov, A. V., Nov 2023, In: Haematologica. 108, 11, p. 3110-3114 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
• 2022

  An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

  Fiedler, W., Montesinos, P., Schliemann, C., Middeke, J., Vasu, S., Scholz, C. W., Esteve, J., Mondal, S., Rüter, B., Burkard, U., Osswald, A. & Blum, W., Dec 2022, In: Haematologica. 107, 12, p. 2977-2982 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  2 Scopus citations

• A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

  Bond, D. A., Huang, Y., Christian, B. A., Jaglowski, S., Benson, D., Alinari, L., Baiocchi, R. A., Cohen, J. B., Blum, K. A. & Maddocks, K. J., 2022, In: Leukemia and Lymphoma. 63, 7, p. 1750-1753 4 p.

  Research output: Contribution to journal › Letter › peer-review
  2 Scopus citations

• A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

  Vasu, S., Altman, J. K., Uy, G. L., Tallman, M. S., Gojo, I., Lozanski, G., Burkard, U., Osswald, A., James, P., Rüter, B. & Blum, W., Mar 2022, In: Haematologica. 107, 3, p. 770-773 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  12 Scopus citations

• Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

  Hyak, J. M., Huang, Y., Rogers, K. A., Bhat, S. A., Grever, M. R., Byrd, J. C., Kittai, A. S., Jones, D., Miller, C. R. & Woyach, J. A., Sep 13 2022, In: Blood Advances. 6, 17, p. 5124-5127 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  12 Scopus citations

• Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients

  Koenig, K. L., Curley, T. P., Mani, S., Keiter, A., Zhao, Q., Behbehani, G. K., Bhatnagar, B., Blachly, J. S., Haque, T. Z., Larkin, K. T. M., Long, M., Mims, A. S., Vasu, S., Wall, S. A., Byrd, J. C., Lustberg, M., Walker, A. R. & Grieselhuber, N. R., Feb 2022, In: Hematological Oncology. 40, 1, p. 115-118 4 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants

  Qu, P., Faraone, J. N., Evans, J. P., Zheng, Y. M., Yu, L., Ma, Q., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J. & Liu, S. L., Oct 6 2022, In: New England Journal of Medicine. 387, 14, p. 1329-1331 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  52 Scopus citations

• Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

  Meyers, G., Hamadani, M., Martens, M., Ali, H., Choe, H., Dawson, P., Harris, A. C., van Hooren, E., Klaassen, W., Leifer, E., MacMillan, M. L., van Oosterhout, Y., Perez, L., Pusic, I., Vo, P. & Levine, J. E., Feb 2022, In: Bone Marrow Transplantation. 57, 2, p. 302-303 2 p.

  Research output: Contribution to journal › Letter › peer-review
  3 Scopus citations

• Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants

  Evans, J. P., Qu, P., Zeng, C., Zheng, Y. M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Mohler, P. J., Gumina, R. J. & Liu, S. L., Jun 16 2022, In: New England Journal of Medicine. 386, 24, p. 2340-2342 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  23 Scopus citations

• Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

  Qu, P., Faraone, J., Evans, J. P., Zou, X., Zheng, Y. M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Mohler, P. J., Gumina, R. J. & Liu, S. L., Jun 30 2022, In: New England Journal of Medicine. 386, 26, p. 2526-2528 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  135 Scopus citations

• Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy

  Jamy, O., Arora, S., Meredith, R., Salzman, D., Di Stasi, A., Minagawa, K., Mineishi, S. & Saad, A., Oct 2022, In: Bone Marrow Transplantation. 57, 10, p. 1597-1599 3 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

  Muhowski, E. M., Ravikrishnan, J., Gordon, B., Yu, L., Misra, S., Walker, B., Eathiraj, S., Sampath, D., Rogers, K. A., Byrd, J. C. & Woyach, J. A., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 166.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Chronic Lymphocytic Leukemia 100%
  • Preclinical Evaluation 100%
  • Venetoclax 100%
  • Nemtabrutinib 100%
  • B-Cell Chronic Lymphocytic Leukemia 100%
  9 Scopus citations

• Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

  Epperla, N., Zhao, Q., Chowdhury, S. M., Shea, L., Moyo, T. K., Reddy, N., Sheets, J., Weiner, D. M., Geethakumari, P. R., Kandarpa, M., Bruno, X. J., Thomas, C., Churnetski, M. C., Hsu, A., Zurbriggen, L., Tan, C., Lindsey, K., Maakaron, J., Caimi, P. F. & Torka, P. & 25 others, Bello, C., Ayyappan, S., Karmali, R., Kim, S. H., Kress, A., Kothari, S., Sawalha, Y., Christian, B., David, K. A., Greenwell, I. B., Janakiram, M., Kenkre, V. P., Olszewski, A. J., Cohen, J. B., Palmisiano, N., Umyarova, E., Wilcox, R. A., Awan, F. T., Alderuccio, J. P., Barta, S. K., Grover, N. S., Ghosh, N., Bartlett, N. L., Herrera, A. F. & Shouse, G., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 96.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Outcome Prediction 100%
  • Ibrutinib 100%
  • Relapsed or Refractory 100%
  • Predictive Factors 100%
  • Marginal Zone Lymphoma 100%
  4 Scopus citations

• Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma

  Bajwa, A., Huang, Y., Li, R., Denlinger, N., Brammer, J., Penza, S., Saad, A., Jaglowski, S. & Kittai, A. S., 2022, In: Leukemia and Lymphoma. 63, 6, p. 1492-1495 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Racial differences as predictors of outcomes in young patients with multiple myeloma

  Bao, A., Zhao, Q., Merritt, E., Bumma, N., Devarakonda, S., Khan, A. M., Umyarova, E., Rosko, A. E., Benson, D. M. & Cottini, F., Jul 2022, In: Blood Cancer Journal. 12, 7, 114.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  4 Scopus citations